Qi Gong as a Method of Craving Reduction in Severe Addict Patients (QICA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03589118|
Recruitment Status : Unknown
Verified July 2019 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : July 17, 2018
Last Update Posted : July 17, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Craving arises in response to an affective tone that is associated with perceptual representations of a sensory object, rather than directly in response to the object.
The investigators presume that qi gong functions to decouple pleasant and unpleasant experience from habitual reactions by removing the affective bias that fuels such emotional reactivity. Qi gong training may specifically target the associated learning process with an emphasis on the critical link between affect and craving in an addictive loop.
|Condition or disease||Intervention/treatment||Phase|
|Alcohol Addiction Alcohol Dependence||Other: Qi Gong sessions||Not Applicable|
The treatment of severe addiction to alcohol and one other or more psychoactive substances sometimes requires hospitalization for complex withdrawal. The medical term " sevrage complexe " is used in this file for hospitalization of patients with multiple addictions or with multiple comorbidities. In the french regulation the duration of hospitalization for " sevrage complexe " is at least 13 days.
The acute period of the first week is sufficient for physical weaning. A period relay for maintaining abstinence beyond the acute phase is a difficult stage. During this period the psychological craving related to the absence of the product causes dysphoria, stress, emotivity and increased difficulty in managing psychological aggression. The risk of relapse is then maximal and favored by many insults of everyday life.
Qi gong is classified by US National Library of Medicine as a mind-body therapy (MBT). It's an ancient traditional Chinese health practice believed to have special healing and recovery power. Today millions of people practice qi gong in China and around the world to treat various diseases. Qi gong is an ecole of breath, relaxation, guided imagery and inward attention. Practice of qi gong is believed to help cleanse the body of toxins, restore energy balance, reduce stress and anxiety. The Baduanjin qigong is one of the most common form of Chinese qi gong.
When going through withdrawal, craving is a psychological urge to administer a discontinued medication or recreational drug. Craving episodes may be triggered by seeing objects or experiencing moments that are associated with the drug or usage of it, and this phenomenon is termed post-acute withdrawal syndrome.
The main goal of our study is to demonstrate a reduction of craving during alcohol and coaddictions withdrawal. This demonstration is of first importance: first for the well-being of the patient during the first weeks after withdrawal, second for drug savings, and third abstinence rate because many authors consider that craving intensity is correlated with relapses risk.
The mind-body techniques of traditional Chinese medicine, as Qigong, are inscribed the number of current approaches in residential treatment. Their transmission would be an additional contribution to the stabilization via active management and motivated patient himself on his health.
The compulsion associated with addictive behavior can be defined as a pathological change in brain plasticity. The pathological learning process induced by the repeated use of the substance is causing behavioral control loss in the vulnerable individual.
Considering the impulsive nature of craving, this study will investigate the driving dynamics of impulses: Trieb "push". Return to the perception supported by the development of attention gestures leaning on the breath, puts us ahead of the motor action and is potentially a mean of influencing compulsive process.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||186 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
Patients are randomized in two groups :
Allocation between groups qi and control is 1 : 1
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||Primary outcome (VAS scale) will be presented to the patient and reported by a study nurse blinded of the randomization arm of the patient.|
|Official Title:||Qi Gong as a Method of Craving Reduction in Severe Addict Patients|
|Actual Study Start Date :||October 4, 2018|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2020|
Experimental: Qi Gong
Qi gong sessions added to usual well defined medical and psychological support
Other: Qi Gong sessions
13 sessions of Qi Gong in a 9 weeks period
No Intervention: Control
Usual well defined medical and psychological support
- Variation of craving intensity [ Time Frame: Change in VAS from baseline to 9 weeks treatment ]
Variation of craving intensity on a Vvisual aAnalogic sScale (VAS) between baseline and the end of the treatment. The intensity is measured by "not at all" (score of 0) and "craving as bad as it could be" or "the most I've ever felt " (maximum score of 10), self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents his craving intensity.
The score is determined by measuring the distance on the 10-cm line between the "no craving" anchor and the patient's mark.
- Evolution over time of craving intensity [ Time Frame: 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline ]
Craving intensity measured with 14-items Obsessive Compulsive Drinking Scale (OCDS).
OCDS score is the sum of two subscales scores. Obsessive Subscale is calculated from items 1 to 6, maximal subscore is 20 (worse outcome).
Compulsive subscale is calculated from items 7 to 14.
- Difference in treatment retention [ Time Frame: 3 weeks and 9 weeks post-baseline ]Difference in treatment retention (permanence rate)
- Evolution over time of total alcohol consumption [ Time Frame: 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline ]Alcohol consumption assessed with Time Line Follow Back (TLFB)
- Evoluation over time of anxiety [ Time Frame: 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline ]
Anxiety questions sum score of Hospital Anxiety and Depression scale (HAD scale). Seven questions are related to anxiety (total A). Anxiety is measured by the sum score questions 1 , 4, 6 , 8, 10 , 12, 14. . Non : Total A = 1,3,5,7,9,11,13
The maximum score being equal to 21 :
0-7: normal; 8-10 bordeline abnormal (borderline case); 11-21 : abnormal (case)
- Evolution over time of depression [ Time Frame: 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline ]
Depression questions sum score of Hospital Anxiety and Depression scale (HAD scale).
Seven questions are related to the depressive dimension (total D). Depression is measured by the sum score questions 2, 3, 5 , 7, 9 , 11, 13 Non: Total D : 2,4,6,8,10,12,14.
The maximum score being equal to 21 :
0-7: normal; 8-10: bordeline abnormal (borderline case); 11-21: abnormal (case)
- Psycological qualitative evaluation [ Time Frame: 1 day, 2 days, 3 days, 4 days, 5 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks and 9 weeks post-baseline ]Qualitative evaluation assessed with clinical notes
- Evolution over time of total alcohol consumption measured by GGT biomarker [ Time Frame: at 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline ]GGT Gamma glutamyl transpeptidase levels in UI/I
- Evolution over time of total alcohol consumption measured by Carbohydrate-Deficient Transferrin (CDT) marker [ Time Frame: at 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline ]CDT levels in %
- Evolution over time of total alcohol consumption measured by Mean Globular Volume (MGV) marker [ Time Frame: at 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline ]MGV levels in fL
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Meets DSM 5 criteria for alcohol use disorder and other substance use disorders
- Alcohol is one of the major abused substances if using multiple substances
- Severity of the disorder defines by the necessity of a complex withdrawal hospitalization.
- Used alcohol in the 3 weeks before hospitalization
- Seeks addiction treatment
- Patient willing to adhere to the study protocol (e.g. attend all visits and follow-ups in the next 3 months).
- Age ≥ 18
- Negative pregnancy test (βHCG) for women of child bearing potential
- Signed informed consent
- Affiliation to the French health insurance (recipient or assign)
- Oral and written comprehension of the french langage
- Pose a current suicidal risk including active suicidal ideation and suicide attempt in the past 30 days
- Non stabilized severe psychiatric comorbidities such as bipolar disorder, schizophrenia, … (at the investigator's discretion)
- Pregnant or breastfeeding women
- Decompensated cirrhosis, liver encephalopathy, neurological complications, severe cognitive impairment and any other severe somatic comorbidity (at the investigator's discretion)
- Currently participated in other interventional clinical study
- Individuals placed under guardianship
- Patient deprived of freedom
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03589118
|Contact: Alain BAUMELOU, MD, Ph.D||01 42 16 05 75 ext firstname.lastname@example.org|
|Contact: Nathalie PLET, Ph.D||01 42 16 05 75 ext email@example.com|
|Hôpital Saint ELOI||Recruiting|
|Montpellier, France, 34000|
|Contact: Hélène DONNADIEU-RIGOLE, MD, PHD 0467337020 ext 0033 firstname.lastname@example.org|
|Hôpital L'ARCHET||Active, not recruiting|
|Nice, France, 06002|
|Groupe Hospitalier Pitié Salpêtrière||Recruiting|
|Paris, France, 75013|
|Contact: Bruno MILLET, MD, PHD 0142162894 ext 0033 email@example.com|
|Principal Investigator:||Alain BAUMELOU, MD, Ph.D||Assistance Publique - Hôpitaux de Paris|
|Study Director:||Nathalie PLET, Ph.D||Assistance Publique - Hôpitaux de Paris|
|Responsible Party:||Assistance Publique - Hôpitaux de Paris|
|Other Study ID Numbers:||
2017-A02986-47 ( Registry Identifier: IDRCB )
|First Posted:||July 17, 2018 Key Record Dates|
|Last Update Posted:||July 17, 2019|
|Last Verified:||July 2019|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|